Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Ponca City, OK
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ponca City, OK
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Medford, OR
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Medford, OR
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Richmond, VA
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Richmond, VA
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Morgantown, WV
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Morgantown, WV
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
Golimumab in Rheumatoid Arthritis Patients With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
A Golimumab Phase 3b, Multicenter, Switch Assessment of Sequential Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Newington, CT
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Newington, CT
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Bettendorf, IA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Bettendorf, IA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Kansas City, KA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Kansas City, KA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Jackson, MS
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jackson, MS
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Lebanon, NH
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lebanon, NH
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Albuquerque, NM
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albuquerque, NM
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Ponca City, OK
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ponca City, OK
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Newington, CT
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Newington, CT
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Jeffersonville, IN
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jeffersonville, IN
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA